Epidemiology Series Forecast Report on Acute Respiratory Distress Syndrome in 11 Major Markets

Acute respiratory distress syndrome (ARDS) is an acute severe lung disease. It most often develops in those admitted to an intensive care unit (ICU), and can be caused by a number of 'triggers', which include trauma to the lungs and pneumonia. ARDS is characterised by wide-spread diffuse injury to the alveolar-capillary membrane, pulmonary inflammation and increased pulmonary vascular permeability. This results in protein-rich non-cardiogenic pulmonary oedema, refractory hypoxaemia and acute respiratory failure.

This report provides the current prevalent population for Diabetic Gastroparesis across 11 Major Markets (USA, France, Germany, Italy, Spain, UK, Japan, Brazil, Poland, Turkey and Netherlands) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team , several of the main symptoms and co-morbidities of ARDS have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

These common ARDS signs and symptoms include:

• Severity as classified by the Berlin definition

• Aetiology of the lung injury

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

• Able to quantify patient populations in global ARDS market to target the development of future products, pricing strategies and launch plans.

• Gain further insight into the prevalence of the subdivided types of ARDS and identify patient segments with high potential.

• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.

• Provide a level of understanding on the impact from specific co-morbid conditions on ARDS prevalent population.

• Identify sub-populations within ARDS which require treatment.

• Gain an understanding of the specific markets that have the largest number of ARDS patients.